PRF1 and cardiomyopathy: Other authors have tested prophylactic as well as therapeutic vaccines based on replication-defective human Type 5 recombinant adenoviruses (rAd) carrying sequences of ASP-2 and TS that resulted in protection against a challenge with the Y and Colombia T. cruzi strains and reversion of cardiomyopathy due to reduced numbers of perforin+ T cells in the heart (Pereira et al., 2015).